https://scholars.lib.ntu.edu.tw/handle/123456789/633537
標題: | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer | 作者: | Geyer, C E Garber, J E Gelber, R D Yothers, G Taboada, M Ross, L Rastogi, P CHIUN-SHENG HUANG et al., |
關鍵字: | BRCA1/2; PARP inhibition; adjuvant therapy; breast cancer; olaparib | 公開日期: | 十二月-2022 | 卷: | 33 | 期: | 12 | 來源出版物: | Annals of oncology : official journal of the European Society for Medical Oncology | 摘要: | The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633537 | ISSN: | 09237534 | DOI: | 10.1016/j.annonc.2022.09.159 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。